Athira Pharma, Inc. (NASDAQ:LONA – Get Free Report)’s stock price shot up 4.4% during trading on Wednesday . The stock traded as high as $8.23 and last traded at $8.23. 11,966 shares were traded during trading, a decline of 61% from the average session volume of 30,709 shares. The stock had previously closed at $7.88.
Analyst Ratings Changes
A number of brokerages have issued reports on LONA. Mizuho raised Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price target for the company in a research note on Thursday, February 19th. Cantor Fitzgerald initiated coverage on Athira Pharma in a research note on Thursday, February 26th. They issued an “overweight” rating on the stock. Zacks Research upgraded Athira Pharma to a “hold” rating in a report on Friday, February 27th. Wall Street Zen raised Athira Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Piper Sandler started coverage on Athira Pharma in a report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.
Get Our Latest Stock Report on LONA
Athira Pharma Stock Performance
Athira Pharma (NASDAQ:LONA – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.73) earnings per share for the quarter. On average, analysts forecast that Athira Pharma, Inc. will post -3.12 EPS for the current fiscal year.
Athira Pharma Company Profile
Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.
Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.
Featured Articles
- Five stocks we like better than Athira Pharma
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
